Answers are grounded in this paper and cite their sources.
Overview reviews evaluate screening tools for sarcopenia, revealing modified versions show better accuracy.
This overview of reviews aims to evaluate the validity of systematic reviews (SRs) and meta-analyses on screening and diagnosis tools for sarcopenia. The methodological quality and the quality of the evidence (QOE) were assessed following the AMSTAR-2 tool and the GRADE approach, respectively. Four SRs were evaluated on SARC-F, while 2 focused on its modified versions, employing both qualitative and quantitative analyses. The 4 SRs analyzed 98 overlapping reports, comprising 51 unique index publications and 26 duplicates. The "% overlaps" for this overview was 50.98%, meanwhile the covered area (CA) was 48.04%, and the corrected CA (CCA) was 30.72%, indicating a very high overlap. When SARC-F was used, results from four records showed a pooled sensitivity ranging from 14 to 77% and pooled specificity from 63 to 94% (QOE: very low to moderate). When its modified versions were used, results from two records showed a pooled sensitivity ranging from 19 to 57% and pooled specificity from 79 to 92% (QOE: low to moderate). AMSTAR-2 assessments revealed that only 10.7% critical domains were unmet, demonstrating high methodological rigor and strong confidence in the findings. Compared to SARC-F, its modified versions show improved performance and can be a more desirable screening tool for sarcopenia. A summary table was compiled to aid clinicians by providing a clear comparison of SARC-F and its modified versions based on the available evidence.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: